JBC INTERFERin siRNA transfection reagent

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M111915200 on January 10, 2002

J. Biol. Chem., Vol. 277, Issue 11, 9155-9159, March 15, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/11/9155    most recent
M111915200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Reeves, C. D.
Right arrow Articles by Katz, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reeves, C. D.
Right arrow Articles by Katz, L.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

A New Substrate Specificity for Acyl Transferase Domains of the Ascomycin Polyketide Synthase in Streptomyces hygroscopicus*

Christopher D. ReevesDagger, Loleta M. Chung, Yaoquan Liu, Qun Xue§, John R. Carney, W. Peter Revill, and Leonard Katz

From Kosan Biosciences, Inc., Hayward, California 94545

Received for publication, December 14, 2001, and in revised form, January 9, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Ascomycin (FK520) is a structurally complex macrolide with immunosuppressant activity produced by Streptomyces hygroscopicus. The biosynthetic origin of C12-C15 and the two methoxy groups at C13 and C15 has been unclear. It was previously shown that acetate is not incorporated into C12-C15 of the macrolactone ring. Here, the acyl transferase (AT) of domain 8 in the ascomycin polyketide synthase was replaced with heterologous ATs by double homologous recombination. When AT8 was replaced with methylmalonyl-CoA-specific AT domains, the strains produced 13-methyl-13-desmethoxyascomycin, whereas when AT8 was replaced with a malonyl-specific domain, the strains produced 13-desmethoxyascomycin. These data show that ascomycin AT8 does not use malonyl- or methylmalonyl-CoA as a substrate in its native context. Therefore, AT8 must be specific for a substrate bearing oxygen on the alpha  carbon. Feeding experiments showed that [13C]glycerol is incorporated into C12-C15 of ascomycin, indicating that both modules 7 and 8 of the polyketide synthase use an extender unit that can be derived from glycerol. When AT6 of the 6-deoxyerythronolide B synthase gene was replaced with ascomycin AT8 and the engineered gene was expressed in Streptomyces lividans, the strain produced 6-deoxyerythronolide B and 2-demethyl-6-deoxyerythronolide B. Therefore, although neither malonyl-CoA nor methylmalonyl-CoA is a substrate for ascomycin AT8 in its native context, both are substrates in the foreign context of the 6-deoxyerythronolide B synthase. Thus, we have demonstrated a new specificity for an AT domain in the ascomycin polyketide synthase and present evidence that specificity can be affected by context.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Ascomycin (FK520) is closely related to tacrolimus (FK506), which is used to prevent xenograft rejection in human patients. Dosing of tacrolimus is difficult because metabolism varies between patients and different co-administered drugs (1-3). Because initial metabolism is due to cytochrome P450-mediated demethylation of the 13-methoxy group (4, 5), we wished to replace the 13-methoxy group with a hydrogen or methyl group and determine whether this increased metabolic stability. Because these analogues could not be obtained by current chemical methods, we sought the desired analogues of ascomycin modified at C13 (Fig. 1) using PKS1 engineering (6, 7).


View larger version (12K):
[in this window]
[in a new window]
 
Fig. 1.   Structures of ascomycin and engineered analogues. The extender unit incorporated by module 8 of the ascomycin PKS and the engineered versions thereof are highlighted with gray in each structure.

The macrolactone precursor of ascomycin is biosynthesized by a large PKS complex consisting of a loading module for a shikimate-derived starter unit; 10 modules for malonyl, methylmalonyl, or other PKS extender units; and a peptide synthetase module for addition of pipecolate (8-13). FK520 and FK506 have methoxy groups at C13 and C15, which could be derived by post-PKS hydroxylation followed by O-methylation or by direct incorporation of an extender unit with an oxygen at the alpha  carbon. Feeding of [13C2]acetate was reported to label C8-C9 and C20-C23 of the macrolactone ring, as expected, but not C12-C15 in either FK520 or FK506 (8). A [1-13C]erythrose feed, used to establish that the dihydroxycyclohexane starter unit is derived from shikimate, unexpectedly labeled C12 and C14, implying that the extender unit is more readily derived from erythrose than from acetate.

Sequence analysis of the ascomycin gene cluster from Streptomyces hygroscopicus (14) showed that it contains close homologues of the genes in the FK506 cluster (9-11) that encode the three PKS subunits, the peptide synthetase, the lysine cyclodeaminase, the C9 hydroxylase, the 31-O-methyltransferase, and the putative 9-hydroxyl oxidase. In the flanking regions of the FK520 cluster, additional genes were found with proposed roles in synthesis of precursors, including a putative methoxymalonyl-ACP precursor for the 13- and 15-methoxy groups of FK520 (14).

The choice of extender unit by a modular PKS system is determined by the acyl transferase (AT) domain of each module (6, 15-17). Comparison of methylmalonyl-CoA- and malonyl-CoA-specific AT domain sequences shows that they cluster into two groups with sequence motifs that diverge according to the specificity of the domain (15). More recently, AT domains specific for ethylmalonyl units have been identified, and they are most closely related to the methylmalonyl-specific domains (18). In addition, there is circumstantial evidence that some domains are specific for an extender unit with oxygen on the alpha  carbon (19-21). Despite the availability of the Escherichia coli malonyl-CoA:ACP transacylase crystal structure (22) and extensive biochemical experiments with both the rat fatty acid synthase and several bacterial PKSs (23-27), the structural basis for AT domain substrate specificity has not been established.

Here we describe replacement of the ascomycin AT8 domain with AT domains specific for malonyl or methylmalonyl extender units, resulting in the production of analogues modified at C13 and showing that ascomycin AT8 is specific for an extender unit bearing oxygen on the alpha  carbon. Precursor labeling experiments showed that ascomycin PKS modules 7 and 8 use an extender unit that can be derived from glycerol. In addition, we show that the specificity of this AT domain can be altered by placing it into a foreign PKS context.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Strains and Media-- The ascomycin-producing strain, S. hygroscopicus ATCC 14891, was plated on SY medium (10 g of soluble starch, 2 g of yeast extract, and 20 g of agar per liter) to prepare spore stocks and grown in TSBGM (tryptic soy broth supplemented with 50 mM TES buffer, pH 7, and 1% glucose) for production of ascomycin or its analogues. Growth and transformation of Streptomyces lividans K4-114 has been described previously (28). Use of the phage vector KC515 followed established procedures (28).

Preparation of Phage Carrying AT Replacement Cassettes-- PKS module 8 was isolated as a 4.6-kb SphI fragment from cosmid pKOS65-C31 (14) and cloned into Litmus28 (New England Biolabs), and the orientation with a unique SacI site proximal to the SpeI site of the polylinker was used (pKOS60-21). A synthetic linker was ligated between the SpeI and SacI sites and then subsequently ligated between the SphI and AflII sites to give pKOS60-29, which was used as a template to isolate regions flanking AT8 by PCR. The PCR mixtures for all reactions described herein contained (50 µl, total volume) 1 µl of template (either diluted plasmid DNA, undiluted genomic DNA, or high-titer phage stock), 10× Pfu buffer, 10× z-deoxynucleotide triphosphate mix (200 µM each deoxynucleotide triphosphate except 100 µM dGTP and 100 µM 7-deaza-dGTP; Roche Molecular Biochemicals), 10% Me2SO, 400 nM of each primer, and 1 µl of cloned Pfu polymerase (Stratagene). Reactions were cycled 25-30 times at 95 °C for 30 s, 60 °C for 30 s, and 72 °C for 2 min. To amplify the 5'-flanking region, the forward primer was 5'-CGACTCACTAGTGGGCAGATCTGGC-3', and one of two reverse primers was used: 1) 5'-CACGCCTAGGCCGGTCGGTCTCGGGCCAC-3', which introduced an AvrII site near the 3' end of the ketoacyl synthase domain, or 2) 5'-GCGGCTAGCTGCTCGCCCATCGCGGGATGC-3', which introduced an NheI site near the 5' end of the AT boundary. These PCR products were cloned as SpeI to AvrII and SpeI to NheI fragments into Litmus28 and Litmus38, respectively, to give pKOS60-37-4 and pKOS60-37-2. The 3'-flanking region was isolated using a forward primer (5'-GATGTACAGCTCGAGTCGGCACGCCCGGCCGCATC-3') that introduced an XhoI site at the AT/dehydratase boundary plus a BsrGI site to facilitate the construction; the reverse primer was 5'-CGACTCACTTAAGCCATGCATCC-3'. This PCR product was isolated as a BsrGI to AflII fragment and ligated into pKOS60-37-4 cut with Acc65I and AflII or pKOS60-37-2 cut with BsrGI and AflII, giving pKOS60-39-13 and pKOSS60-39-1, respectively.

Heterologous AT domains were obtained by PCR using primers that introduced AvrII and XhoI or NheI and XhoI sites at the 5' and 3' ends, respectively. Each heterologous AT was cloned into pKOS60-39-13 (AvrII-XhoI) or pKOS60-39-1 (NheI-XhoI) to create a series of AT replacement cassettes. Each replacement cassette was isolated as a BglII to NsiI fragment and ligated to KC515 DNA cut with BamHI and PstI, and the ligation mixture was introduced into S. lividans TK24 by transfection. The resulting plaques were purified, and high-titer phage stocks were prepared as described previously (28). Recombinant phage preparations were checked by PCR using a pair of primers annealing within the dehydratase/keto reductase-flanking sequence.

Construction of Strains with AT8 Replaced by Heterologous ATs-- Spores of S. hygroscopicus (107) were suspended in Difco nutrient broth, heat-shocked at 50 °C for 10 min, and mixed with an equal number of plaque-forming units of recombinant phage in Difco nutrient broth. The mixture was spread on R2YE plates (28), and after an overnight incubation at 30 °C, plates were overlaid with 1.25 mg of thiostrepton suspended in 1 ml of H2O. After 7-10 days, sporulating colonies were streaked on SY agar containing 50 µg/ml thiostrepton. Colonies were picked from these plates after about 5 days and macerated in 200 µl of H2O using a microfuge pestle. Half the suspension was inoculated into a 25 × 150-mm tube with two 4-mm glass beads and 5 ml of TSBGM; the other half was inoculated into the same medium with 50 µg/ml thiostrepton. After 2-3 days, a 1.5-ml sample of each thiostrepton-containing culture was harvested for total DNA isolation, and a 0.75-ml sample was prepared for LC-MS analysis by adding an equal volume of MeCN and clarifying by centrifugation. DNA was isolated by the SDS, proteinase K, phenol method (28) and analyzed by Southern blot hybridization using the digoxigenin labeling and detection kits supplied by Roche Molecular Biochemicals. Each culture grown without thiostrepton was spread on an SY agar plate to obtain spores to screen for the second recombination event.

Selected spore preparations from the nonselective propagation plates above were titered and spread on several plates at about 100-200 colonies/plate. When colonies were sufficiently sporulated, they were replica-plated onto SY agar plates containing 50 µg/ml thiostrepton. After 4-5 days, putative thioS recombinants were identified and clonally isolated. These were grown in 5-ml TSBGM tube cultures for 3 days, and the broth was extracted as described above for LC-MS analysis (see below). Strains producing 13-DMA or 13-MDMA were designated KOS45-170 and KOS60-135, respectively.

Precursor Labeling Studies-- [13C2]Glycine and [13C3]glycerol were obtained from Cambridge Isotope Laboratories. [13C2]Glycolate, a mixture of ethyl [13C2]bromoacetate (Aldrich; 98% 13C; 1.0 g), sodium acetate (1.0 g), and anhydrous N,N-dimethylformamide (15 ml), was stirred at 80 °C for 3 h. Water was added, and the mixture was extracted three times with Et2O. The combined organic layers were washed twice with H2O, washed once with brine, and dried over Na2SO4. After removal of solvent, a clear oil (0.45 g) was obtained. 1H NMR (CDCl3): delta  4.59 (2H, dd, J = 149, 4.8 Hz), 4.23 (2H, qd, J = 7.2, 3.2 Hz), 2.16 (3H, s), 1.29 (3H, t, J = 7.2 Hz). The acetate was dissolved in MeOH (15 ml), 0.5 M LiOH (15 ml) was added, and the mixture was stirred overnight at room temperature. After neutralization with 2 N HCl, the mixture was extracted twice with ether. The aqueous layer was dried under high vacuum to give [13C2]lithium glycolate (508 mg; containing some sodium acetate and NaCl). 1H NMR (D2O): delta  3.88 (2H, dd, J = 143.6, 4.4 Hz). 13C NMR (D2O): delta  179.1 (d, J = 55 Hz), 60.3 (d, J = 55 Hz).

[methyl-13C]Methoxyacetic acid:ethyl diazoacetate (1.8 ml) was added dropwise to a stirred solution of Rh2(OAc)4 (10 mg) in [13C]methanol (Isotec; 99 atom% 13C; 1.0 g). After 4 h, the mixture was diluted with 10 ml of hexanes and filtered through a 1 cm plug of silica gel. The silica was washed with 3:1 hexanes/ether, and the eluates were combined and concentrated to give 1.35 g of ethyl [methyl-13C]methoxyacetate as a colorless liquid. 1H NMR (CDCl3): delta  4.24 (2H, q, J = 7.2 Hz), 4.03 (2H, d, JCH = 4.8 Hz), 3.45 (3H, d, JCH = 142 Hz), 1.31 (3H, t, J = 7.2 Hz). The ester was dissolved in 2 ml of MeOH and treated with 10 ml of 6 N NaOH for 12 h. The mixture was extracted three times with CH2Cl2, and then the aqueous phase was acidified to below pH 2 using concentrated HCl and diluted with 100 ml of saturated aqueous NaCl before continuous extraction with ether for 24 h. The ether extract was dried over MgSO4, filtered, and evaporated to yield 1.5 g of an oil. Bulb-to-bulb distillation under reduced pressure yielded clean [methyl-13C]methoxyacetic acid (0.70 g). 1H NMR (CDCl3): delta  4.09 (2H, d, JCH = 4.8 Hz), 3.48 (3H, d, JCH = 142 Hz).

[methyl-13C]Methoxymalonic acid:5-diazo-Meldrum's acid (2 g), [13C]methanol (2 g), Rh2(OAc)4 (250 mg), and toluene (25 ml) were mixed in an Ace pressure tube. The capped tube was heated at 140 °C for 2 h, the reaction was filtered, and the filtrate was evaporated. The residue was dissolved in H2O and extracted three times with EtOAc. The combined organic layers were dried over MgSO4, filtered, and evaporated to yield an oil (1.3 g), which was identified as a mixture of dimethyl methoxymalonate and monomethyl methoxymalonate. The oil was dissolved in MeOH (5 ml), 6 N NaOH (10 ml) was added, and the mixture was left overnight at room temperature. After cooling on ice, the mixture was acidified to pH < 1 with HCl and filtered. The filtrate was dried under high vacuum to yield a yellow solid (1 g). To remove the inorganic salt, the solid was extracted three times with acetone; the acetone extracts were evaporated to give methoxymalonic acid as a solid (0.65 g). 1H NMR (acetone-d6): delta  4.47 (1H, d, J = 4 Hz), 3.46 (3H, d, J = 143 Hz). 13C NMR (acetone-d6): delta  167.0, 79.9, 57.5 (enriched).

Cultures grown in TSBGM were harvested at 24 h, washed twice, and resuspended in 100 mM MES, pH 6.0, 1% glucose to the original culture volume. The resting cell suspension was shaken in baffled flasks at 30 °C and 175 rpm. The 13C-labeled precursors were added in three equal portions at 24, 36, and 48 h to obtain 0.5 g/liter final concentration. Resting cell cultures were harvested at 56 h by adding half the volume of the culture of MeOH. The resulting broth/extract was clarified by centrifugation and loaded at 25 ml/min onto a column of Diaion HP-20ss pre-equilibrated in MeOH-H2O (2:1). The column volume was <FR><NU>1</NU><DE>20</DE></FR> the volume of the broth/extract. The column was eluted at 8 ml/min with MeOH-H2O at ratios of 1:2 (2 column volumes), 1:1 (4 column volumes), 7:3 (4 column volumes), and 9:1 (4 column volumes). The 9:1 eluent was concentrated to give crude ascomycin, which was chromatographed over Bond-Elut ODS solid phase extraction cartridges by eluting with MeOH-H2O (9:1). This material was suitable for NMR analysis.

Expression of DEBS with AT6 Replaced by Ascomycin AT8-- The Streptomyces expression vector pKAO127 containing the SCP2* replicon and the DEBS genes expressed via the actI promoter and actII-ORF4 transcription activator were described previously (29). Constructs with SpeI and PstI sites engineered at the eryAT6 boundaries have also been described previously (6). The ascomycin AT8 was isolated by PCR with primers that introduced a SpeI site at the 5' boundary and an NsiI site at the 3' boundary. The PCR product was cloned into Litmus28 to give pKOS38-178, which was checked by sequencing, and subsequently inserted between the engineered SpeI and PstI sites flanking DEBS AT6. This was assembled into the DEBS expression construct pKOS38-187. The construct was introduced into S. lividans K4-114 by standard protoplast transformation (28), and the transformants were cultured in R5 medium for production of the 6-DEB analogue.

LC-MS Analysis-- Samples were analyzed by on-line extraction by LC-MS using a system comprised of a 10 port, 2 position switching valve/injector, Beckman System Gold HPLC, an Alltech evaporative light scattering detector, and a PE SCIEX API100 LC-mass spectrometer equipped with an atmospheric pressure chemical ionization source. For ascomycin analogue analyses, whole cultures were extracted by adding 1 volume of MeCN and clarified by centrifugation. Sample (250 µl) was loaded onto an Upchurch 4.3 × 10 mm ODS guard column that had been pre-equilibrated for 1 min with 0.1% acetic acid at 1 ml/min, with the eluate being diverted to waste. At 30 s postinjection a linear gradient to 1:1 MeCN-H2O (0.1% acetic acid) over 1 min was started, with the eluate still diverted to waste. At 2 min, the direction of flow through the guard column was reversed, and the eluent was diverted onto a Metachem Inertsil ODS-3 column (5 µm; 4.6 × 150 mm) at 50 °C pre-equilibrated with 1:1 MeCN-H2O (0.1% acetic acid). A linear gradient from 50% to 100% MeCN (0.1% acetic acid) at 1 ml/min over 5 min and then 100% MeCN (0.1% acetic acid) for 4 min was monitored by evaporative light scattering and mass spectrometry. For 6-DEB and 2-demethyl-6-DEB, 100 µl of clarified whole broth was loaded onto the guard column after a 1 min pre-equilibration with H2O at 1 ml/min. At 30 s postinjection, a linear gradient to 15% MeCN over 1 min was initiated. At 2 min, the direction of flow through the guard column was reversed, and the eluent was diverted onto a Metachem Inertsil ODS-3 column (5 µm; 4.6 × 150 mm) pre-equilibrated with 15% MeCN. A linear gradient from 15% to 100% MeCN at 1 ml/min over 6 min and then 100% MeCN for 3 min was monitored by evaporative light scattering and mass spectrometry.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Replacement of AT8 in the Ascomycin PKS-- We previously hypothesized that AT8 of the ascomycin PKS selects the unusual precursor methoxymalonyl-ACP leading to direct incorporation of the methoxy group at C13 (14). To explore this, ascomycin AT8 was replaced with heterologous ATs of known specificity by double homologous recombination using the phage vector KC515 as shown in Fig. 2. Between 10 and 100 thiostrepton-resistant colonies were obtained after infection with recombinant phages, whereas KC515 alone gave no thiostrepton-resistant colonies. Ten isolates each of lysogens from the rapamycin AT3 or erythromycin AT2 construct were analyzed in detail. None produced detectable ascomycin or related products, consistent with insertion of the phage into a gene essential for ascomycin production. Southern blot hybridization experiments (using XhoI or Acc65I digestion of genomic DNA) showed that of the erythromycin AT2 lysogens, seven arose by recombination at the ketoacyl synthase 8 sequence, and three arose by recombination at the dehydratase 8/keto reductase 8 sequence, whereas of the rapamycin AT3 lysogens, eight recombined at the dehydratase 8/keto reductase 8 sequence, one recombined at the ketoacyl synthase 8, and one apparently recombined at the dehydratase 1/keto reductase 1 sequence, which is 98% identical over 1 kb with keto reductase 8/dehydratase 8. Three lysogens from the malonyl-specific rapamycin AT12 construct also did not produce FK520, and the expected first crossover event was verified using PCR.


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 2.   Diagram showing how S. hygroscopicus strains were engineered to replace AT8 in the ascomycin PKS with AT domains of other specificity. Each AT replacement cassette was delivered on the KC515 phage vector, and thiostrepton-resistant recombinants were selected. Isolates that had crossed over at either the ketoacyl synthase 8 or dehydratase 8 sequence were observed by Southern blot analyses. Analysis of the thioS isolates indicated that both types of second crossover events occurred, giving wild-type revertants or strains containing the heterologous AT replacement, which produced the predicted ascomycin analogue. See "Experimental Procedures" for details.

After growth in the absence of selection, thioS colonies appeared at a frequency of about 0.3%, half of which produced ascomycin and had therefore reverted to wild-type. With the exception of one thioS recombinant that produced no ascomycin-related compound, the remaining thioS recombinants produced a compound with an LC retention time and atomic mass consistent with either 13-DMA (for the rapamycin AT12 replacement) or 13-MDMA (for the rapamycin AT3 and erythromycin AT2 replacements). The overall statistics indicated little bias for recombination via one flanking sequence over the other. After growing selected strains in laboratory-scale stirred-tank fermenters and purifying the ascomycin analogues, structures were verified by mass spectrometry and NMR analyses.2 For the rapamycin AT3 replacement strain, only 13-MDMA was produced, and the relative stereochemistry of the 13-methyl group was the same as that of the 13-methoxy group of ascomycin. Thus, the alpha -methyl epimerization activity that occurs in rapamycin module 3 does not appear to reside on the AT domain, consistent with previous work (23). The 13-DMA and 13-MDMA analogues were produced at levels about 5% of parental ascomycin titers (50 mg/liter), which is better than most PKS engineering results (6). For the rapamycin AT12 replacement strain, 13-DMA was the predominant product, but a small amount (~5% of the total) of ascomycin was also observed, even after two rounds of clonal isolation. A summary of the products identified in cultures of the engineered strains is presented in Table I.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Summary of results from replacement of AT8 in the ascomycin PKS

Incorporation of 13C-labeled Precursors into Ascomycin-- It was reported previously that [1,2-13C]acetate can be incorporated into the macrolactone ring carbons C8, C9, and C20-C23 but not C12-C15 in either ascomycin or FK506 (8). To explore the origin of C12-C15 further, the incorporation of potential 13C-labeled precursors ([13C2]glycolate, [methyl-13C]methoxyacetate, [methyl-13C]methoxymalonate, [13C2]glycine, and [13C3]glycerol) was evaluated by 13C NMR experiments (Table II). No significant enrichment of the O-methyl carbon atoms was seen if either [methyl-13C]methoxyacetate or [methyl-13C]methoxymalonate was fed. In addition, no detectable coupled signals at C12-C15 were seen after feeding glycolate. Glycine gave weak coupled signals at C12-C15 and additional weak signals for the O-methyl carbons (at C13, C15, and C31), presumably because of metabolism via the one-carbon pool. On the other hand, glycerol feeding gave unequivocal signals resulting from 1JC-C for C12-C13 and C14-C15, indicating intact incorporation of two-carbon units at these positions (Table II).

                              
View this table:
[in this window]
[in a new window]
 
Table II
13C enrichment of C12-C15 fragment in ascomycin after the feeding of various precursors

Expression of DEBS with AT6 Replaced by Ascomycin AT8-- Replacement of DEBS AT6 by the malonyl-specific rapamycin AT2 and expression in S. lividans was previously shown to give production of 2-demethyl-6-DEB instead of 6-DEB (6). To further study the ascomycin AT8 domain, the same fusion junctions engineered in this previous construct were used to replace DEBS AT6 with ascomycin AT8. LC-MS analysis of S. lividans cultures expressing this construct revealed that 6-DEB and 2-demethyl-6-DEB (Fig. 3) were produced at ~7 and 3 mg/liter, respectively, or 10-20% the level of 6-DEB produced by S. lividans cultures expressing the wild-type DEBS genes. No 2-methoxy-2-demethyl-6-DEB was observed. Thus, ascomycin AT8 in this foreign PKS context, expressed in a strain that does not contain the methoxymalonyl precursor, selects either malonyl-CoA or methylmalonyl-CoA as alternative substrate relatively efficiently.


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 3.   Structure of 6-DEB and potential analogues. S. lividans expressing DEBS produces predominantly 6-DEB. S. lividans expressing DEBS with AT6 replaced by ascomycin AT8 produces 6-DEB and 2-demethyl-6-DEB. No 2-methoxy-2-demethyl-6-DEB was detected. The portion of the molecules arising from incorporation by DEBS module 6 is boxed.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The results of AT8 replacement in the ascomycin PKS have proven that module 8 uses a precursor other than malonyl-CoA or methylmalonyl-CoA. Moreover, we have shown that C12-C15 arise by sequential incorporation of an extender unit that can be derived from glycerol, consistent with our previous proposal, based on gene homologies, that the direct precursor comes from the glycolytic pathway (14). Recent results have confirmed that replacement of AT7 with ATs specific for malonyl, methylmalonyl, or ethylmalonyl extenders gave the predicted 15-desmethoxy analogue.3 Two possible reasons glycolate was not incorporated are that it was not taken up by the cells or that one of the activities needed to convert it to glycerate (e.g. tartronate semialdehyde synthase) was absent from S. hygroscopicus under the growth conditions used.

Our results are consistent with the proposal that methoxymalonyl-ACP is the substrate used by modules 7 and 8 (14). The substrate is more likely to be a methoxymalonyl thioester rather than a hydroxymalonyl thioester for the following reasons. First, aside from fkbM, the assigned 31-O-methyltransferase gene, fkbG is the only other methyltransferase gene found in the cluster (14). It is unlikely that FkbG methylates both the 13- and 15- hydroxyl groups of a post-PKS intermediate because methyltransferases are known to have very tight substrate specificity. Second, the sequence of FkbG is most similar to two methyltransferases encoded in clusters for macrolides with a methoxy group at an alpha  carbon and is more similar to plant caffeoyl-CoA methyltransferases than to any of the enzymes known to methylate a post-PKS macrolide intermediate (14). This is consistent with FkbG methylating a precursor to the extender unit before its incorporation into the polyketide chain. Finally, if hydroxymalonyl units were incorporated at these positions, the polyketide would rearrange to form the hemiketal isomers known to be favored following demethylation of these methoxy groups by mammalian liver CYP3A (4, 5), and this could interfere with subsequent biosynthetic steps. Our previous proposal that the substrate is methoxymalonyl-ACP instead of methoxymalonyl-CoA was based on the presence of an unusual ACP gene (fkbJ) in the set of five genes believed to encode the synthesis of this extender unit (14). If this hypothesis is correct, methoxymalonyl-specific AT domains may recognize features of the unusual ACP as an additional way to maintain tight substrate specificity.

The choice of precursor by a given AT domain is governed by its relative selectivity for the available substrates and the effective concentrations of those substrates. Clearly, there is an adequate supply of both malonyl-CoA and methylmalonyl-CoA in S. hygroscopicus during ascomycin production because these precursors are incorporated by other modules of the ascomycin PKS. Despite this, AT8 in its native ascomycin PKS context discriminates against these substrates because the corresponding analogues have never been observed from the wild-type strain. In addition, when the fkbG gene was disrupted, no ascomycin-related structures were detected,4 showing that AT8 (and AT7) discriminates against malonyl-CoA or methylmalonyl-CoA in its native context.

Extender unit specificity is usually tight, although there are examples of relaxed specificity, such as module 4 of the epothilone PKS, which incorporates either malonyl or methylmalonyl units (30, 31), and modules in the ascomycin and monensin PKSs, which can incorporate ethylmalonyl or methylmalonyl units (8, 32). Rapamycin AT12, which is specific for malonyl-CoA in its native context, accepted the methoxymalonyl substrate to some extent, i.e. about 5% of the product from the engineered strain was ascomycin in the ascomycin PKS context. When ascomycin AT8 was placed into the context of DEBS module 6, both methylmalonyl-CoA and malonyl-CoA were used efficiently as substrates, even though the domain rejects these substrates in the native context, as discussed above. Recently, genes encoding methoxymalonyl-ACP biosynthesis from the ansamitocin gene cluster of Actinosynnema pretiosum were co-expressed along with the engineered DEBS genes in S. lividans, and the resulting strain produced 2-methoxy-2-demethyl-6-DEB.5 This shows that ascomycin AT8 maintains its original substrate preference in this foreign context. On the other hand, our results also suggest that changing the context of an AT domain can affect substrate selectivity. We hypothesize that external steric forces on a domain after folding and assembly of the PKS complex can change the conformation of a domain sufficiently to affect its specificity. Replacement of a short segment of amino acids toward the C terminus of AT domains, which lies outside the homology with E. coli transacylase and is probably on the exterior of the domain, also has been shown to alter specificity (24). Perhaps this region is important for the interaction of the AT domain with the rest of the PKS complex and thus can affect specificity by the mechanism hypothesized here.

Although primary sequence motifs have been identified that play a role in substrate specificity (15, 33), it has not yet been possible to identify sequence motifs correlated with specificity for the methoxymalonyl substrate. Indeed, AT domains specific for methoxymalonyl substrates appear to have evolved from either malonyl-specific domains, as in the case of the ascomycin PKS, or from methylmalonyl-specific domains, as in the case of the niddamycin and soraphen PKSs (18, 34).

    FOOTNOTES

* This work was supported in part by SBIR Grant 1R43AI46206-01A1 from the National Institutes of Health.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Kosan Biosciences, Inc., 3832 Bay Center Place, Hayward, CA 94545. Tel.: 510-732-8400; Fax: 510-732-8401; E-mail: reeves@kosan.com.

§ Present address: Darden Graduate School of Business Administration, University of Virginia, Charlottesville, VA 22906.

Published, JBC Papers in Press, January 10, 2002, DOI 10.1074/jbc.M111915200

2 J. Carney, R. Arslanian, E. Woo, and G. Ashley, manuscript in preparation.

3 A. Schirmer, W. P. Revill, and L. Katz, unpublished data.

4 M. Trujillo, W. P. Revill, and L. Katz, unpublished data.

5 Y. Kato, L. Bai, Q. Xue, W. P. Revill, T.-W. Yu, and H. G. Floss, submitted for publication.

    ABBREVIATIONS

The abbreviations used are: PKS, polyketide synthase; ACP, acyl carrier protein; AT, acyl transferase (appended number designates the module where the domain is from); LC-MS, liquid chromatography-mass spectrometry; 13-DMA, 13-desmethoxyascomycin; 13-MDMA, 13-methyl-13-desmethoxyascomycin; 6-DEB, 6-deoxyerythronolide B; DEBS, deoxyerythronolide B synthase; thioS, thiostrepton-sensitive.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Sewing, K. F. (1994) Transplant. Proc. 26, 3267-3269[Medline] [Order article via Infotrieve]
2. Iwasaki, K., Matsuda, H., Nagase, K., Shiraga, T., Tokuma, Y., and Uchida, K. (1993) Res. Commun. Chem. Pathol. Pharmacol. 82, 209-216[Medline] [Order article via Infotrieve]
3. Lampen, A., Christians, U., Guengerich, F. P., Watkins, P. B., Kolars, J. C., Bader, A., Gonschior, A. K., Dralle, H., Hackbarth, I., and Sewing, K. F. (1995) Drug Metab. Dispos. 23, 1315-1324[Abstract]
4. Iwasaki, K., Shiraga, T., Matsuda, H., Nagase, K., Tokuma, Y., Hata, T., Fujii, Y., Sakuma, S., Fujitsu, T., and Fujikawa, A. (1995) Drug Metab. Dispos. 23, 28-34[Abstract]
5. Shiraga, T., Matsuda, H., Nagase, K., Iwasaki, K., Noda, K., Yamazaki, H., Shimada, T., and Funae, Y. (1994) Biochem. Pharmacol. 47, 727-735[CrossRef][Medline] [Order article via Infotrieve]
6. McDaniel, R., Thamchaipenet, A., Gustafsson, C., Fu, H., Betlach, M., and Ashley, G. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 1846-1851[Abstract/Free Full Text]
7. Katz, L. (1997) Chem. Rev. 97, 2557-2576[CrossRef][Medline] [Order article via Infotrieve]
8. Byrne, K. M., Shafiee, A., Nielson, J., Arison, B., Monaghan, R. L., and Kaplan, L. (1993) Dev. Ind. Microbiol. 32, 29-45
9. Motamedi, H., Shafiee, A., Cai, S. J., Streicher, S. L., Arison, B. H., and Miller, R. R. (1996) J. Bacteriol. 178, 5243-5248[Abstract/Free Full Text]
10. Motamedi, H., Cai, S. J., Shafiee, A., and Elliston, K. O. (1997) Eur. J. Biochem. 244, 74-80[Medline] [Order article via Infotrieve]
11. Motamedi, H., and Shafiee, A. (1998) Eur. J. Biochem. 256, 528-534[Medline] [Order article via Infotrieve]
12. Nielsen, J. B., Hsu, M. J., Byrne, K. M., and Kaplan, L. (1991) Biochemistry 30, 5789-5796[CrossRef][Medline] [Order article via Infotrieve]
13. Shafiee, A., Motamedi, H., Dumont, F. J., Arison, B. H., and Miller, R. R. (1997) J. Antibiot. (Tokyo) 50, 418-423[Medline] [Order article via Infotrieve]
14. Wu, K., Chung, L., Revill, W. P., Katz, L., and Reeves, C. D. (2000) Gene (Amst.) 251, 81-90[CrossRef][Medline] [Order article via Infotrieve]
15. Haydock, S. F., Aparicio, J. F., Molnar, I., Schwecke, T., Khaw, L. E., Konig, A., Marsden, A. F., Galloway, I. S., Staunton, J., and Leadlay, P. F. (1995) FEBS Lett. 374, 246-248[CrossRef][Medline] [Order article via Infotrieve]
16. Kuhstoss, S., Huber, M., Turner, J. R., Paschal, J. W., and Rao, R. N. (1996) Gene (Amst.) 183, 231-236[CrossRef][Medline] [Order article via Infotrieve]
17. Oliynyk, M., Brown, M. J., Cortes, J., Staunton, J., and Leadlay, P. F. (1996) Chem. Biol. 3, 833-839[CrossRef][Medline] [Order article via Infotrieve]
18. Kakavas, S. J., Katz, L., and Stassi, D. (1997) J. Bacteriol. 179, 7515-7522[Abstract/Free Full Text]
19. Haber, A., Johnson, R. D., and Rinehart, K. L. J. (1977) J. Am. Chem. Soc. 99, 3541-3544[CrossRef][Medline] [Order article via Infotrieve]
20. Hill, A. M., Harris, J. P., and Siskos, A. P. (1998) Chem. Commun. 1998, 2361-2362[CrossRef]
21. Ono, M., Sakuda, S., Ikeda, H., Furihata, K., Nakayama, J., Suzuki, A., and Isogai, A. (1998) J. Antibiot. (Tokyo) 51, 1019-1028[Medline] [Order article via Infotrieve]
22. Serre, L., Verbree, E. C., Dauter, Z., Stuitje, A. R., and Derewenda, Z. S. (1995) J. Biol. Chem. 270, 12961-12964[Abstract/Free Full Text]
23. Khosla, C., Gokhale, R. S., Jacobsen, J. R., and Cane, D. E. (1999) Annu. Rev. Biochem. 68, 219-253[CrossRef][Medline] [Order article via Infotrieve]
24. Lau, J., Fu, H., Cane, D. E., and Khosla, C. (1999) Biochemistry 38, 1643-1651[CrossRef][Medline] [Order article via Infotrieve]
25. Marsden, A. F., Caffrey, P., Aparicio, J. F., Loughran, M. S., Staunton, J., and Leadlay, P. F. (1994) Science 263, 378-380[Abstract/Free Full Text]
26. Rangan, V. S., and Smith, S. (1997) J. Biol. Chem. 272, 11975-11978[Abstract/Free Full Text]
27. Rangan, V. S., Serre, L., Witkowska, H. E., Bari, A., and Smith, S. (1997) Protein Eng. 10, 561-566[Abstract/Free Full Text]
28. Kieser, T., Bibb, M. J., Buttner, M. J., Chater, K. F., and Hopwood, D. A. (2000) Practical Streptomyces Genetics , The John Innes Foundation, Norwich, United Kingdom
29. Kao, C. M., Katz, L., and Khosla, C. (1994) Science 265, 509-512[Abstract/Free Full Text]
30. Julien, B., Shah, S., Ziermann, R., Goldman, R., Katz, L., and Khosla, C. (2000) Gene (Amst.) 249, 153-160[CrossRef][Medline] [Order article via Infotrieve]
31. Tang, L., Shah, S., Chung, L., Carney, J., Katz, L., Khosla, C., and Julien, B. (2000) Science 287, 640-642[Abstract/Free Full Text]
32. Liu, H., and Reynolds, K. A. (1999) J. Bacteriol. 181, 6806-6813[Abstract/Free Full Text]
33. Reeves, C. D., Murli, S., Ashley, G. W., Piagentini, M., Hutchinson, C. R., and McDaniel, R. (2001) Biochemistry 40, 15464-15470[CrossRef][Medline] [Order article via Infotrieve]
34. Schupp, T., Toupet, C., Cluzel, B., Neff, S., Hill, S., Beck, J. J., and Ligon, J. M. (1995) J. Bacteriol. 177, 3673-3679[Abstract/Free Full Text]


Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
MicrobiologyHome page
Y. Sun, H. Hong, M. Samborskyy, T. Mironenko, P. F. Leadlay, and S. F. Haydock
Organization of the biosynthetic gene cluster in Streptomyces sp. DSM 4137 for the novel neuroprotectant polyketide meridamycin
Microbiology, December 1, 2006; 152(12): 3507 - 3515.
[Abstract] [Full Text] [PDF]


Home page
MicrobiologyHome page
S. F. Haydock, A. N. Appleyard, T. Mironenko, J. Lester, N. Scott, and P. F. Leadlay
Organization of the biosynthetic gene cluster for the macrolide concanamycin A in Streptomyces neyagawaensis ATCC 27449
Microbiology, October 1, 2005; 151(10): 3161 - 3169.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/11/9155    most recent
M111915200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Reeves, C. D.
Right arrow Articles by Katz, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reeves, C. D.
Right arrow Articles by Katz, L.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.